Related references
Note: Only part of the references are listed.Safety of breast feeding during rituximab treatment in multiple sclerosis
Brit Ellen Rod et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2023)
Twin study reveals non-heritable immune perturbations in multiple sclerosis
Florian Ingelfinger et al.
NATURE (2022)
Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM
Tobias Lanz et al.
NATURE (2022)
Longitudinal Analysis Suggests Epstein--Barr as Cause of Multiple Sclerosis
[Anonymous]
CLINICAL PHARMACOLOGY & THERAPEUTICS (2022)
Population Pharmacokinetic-B Cell Modeling for Ofatumumab in Patients with Relapsing Multiple Sclerosis
Huixin Yu et al.
CNS DRUGS (2022)
Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years
Stephen L. Hauser et al.
MULTIPLE SCLEROSIS JOURNAL (2022)
Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy
Maria Pia Sormani et al.
EBIOMEDICINE (2022)
COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab
Anne H. Cross et al.
NEUROLOGY AND THERAPY (2022)
Clinical outcomes of COVID-19 in patients with multiple sclerosis treated with ocrelizumab in the pre- and post-SARS-CoV-2 vaccination periods: Insights from Israel
Janick Weberpals et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2022)
Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial
Anders Svenningsson et al.
LANCET NEUROLOGY (2022)
Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies
Irene Schiavetti et al.
MULTIPLE SCLEROSIS JOURNAL (2022)
Ofatumumab Modulates Inflammatory T Cell Responses and Migratory Potential in Patients With Multiple Sclerosis
Marina Rode von Essen et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2022)
Broader Epstein-Barr virus-specific T cell receptor repertoire in patients with multiple sclerosis
Tilman Schneider-Hohendorf et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2022)
Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis
Lawrence Steinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis
Kjetil Bjornevik et al.
SCIENCE (2022)
A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis
Edward Fox et al.
MULTIPLE SCLEROSIS JOURNAL (2021)
White matter lesions in multiple sclerosis are enriched for CD20dim CD8+ tissue-resident memory T cells
Cheng-Chih Hsiao et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2021)
Incidence, Clinical Features, and Outcomes of Late-Onset Neutropenia From Rituximab for Autoimmune Disease
Reza Zonozi et al.
ARTHRITIS & RHEUMATOLOGY (2021)
Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis
Maria P. Sormani et al.
ANNALS OF NEUROLOGY (2021)
COVID-19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response
Ana Zabalza et al.
EUROPEAN JOURNAL OF NEUROLOGY (2021)
Anti-CD20 therapies and pregnancy in neuroimmunologic disorders A cohort study from Germany
Tania Kuempfel et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2021)
Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study
Anat Achiron et al.
JOURNAL OF NEUROIMMUNOLOGY (2021)
COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021
Anat Achiron et al.
MULTIPLE SCLEROSIS JOURNAL (2021)
Progressive Multifocal Leukoencephalopathy in a Patient With Progressive Multiple Sclerosis Treated With Ocrelizumab Monotherapy
Arpan Patel et al.
JAMA NEUROLOGY (2021)
Comparison of the Efficacy and Safety of Anti-CD20 B Cells Depleting Drugs in Multiple Sclerosis
Kelly R. Cotchett et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2021)
Proinflammatory CD20+ T Cells are Differentially Affected by Multiple Sclerosis Therapeutics
Corinna Quendt et al.
ANNALS OF NEUROLOGY (2021)
Ectopic lymphoid follicles in progressive multiple sclerosis: From patients to animal models
Jiangshan Zhan et al.
IMMUNOLOGY (2021)
Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy
Sokratis A. Apostolidis et al.
NATURE MEDICINE (2021)
Humoral and T-Cell Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Ocrelizumab
Livnat Brill et al.
JAMA NEUROLOGY (2021)
Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies
Maria Pia Sormani et al.
EBIOMEDICINE (2021)
Minimal breast milk transfer of rituximab, a monoclonal antibody used in neurological conditions
Kristen M. Krysko et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2020)
Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients
Peter Alping et al.
ANNALS OF NEUROLOGY (2020)
Late onset absolute neutropenia associated with ocrelizumab treatment in multiple sclerosis: A case report and review of the literature
Chiara Zanetta et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2020)
Anti-CD20–mediated B-cell depletion in autoimmune diseases: successes, failures and future perspectives
Etienne Crickx et al.
KIDNEY INTERNATIONAL (2020)
Structure of CD20 in complex with the therapeutic monoclonal antibody rituximab
Lionel Rouge et al.
SCIENCE (2020)
Epstein-Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies
Amit Bar-Or et al.
TRENDS IN MOLECULAR MEDICINE (2020)
Tissue-resident memory T cells invade the brain parenchyma in multiple sclerosis white matter lesions
Nina L. Fransen et al.
BRAIN (2020)
B and T Cells Driving Multiple Sclerosis: Identity, Mechanisms and Potential Triggers
Jamie van Langelaar et al.
FRONTIERS IN IMMUNOLOGY (2020)
Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis
Celine Louapre et al.
JAMA NEUROLOGY (2020)
Late-onset neutropenia after RITUXIMAB therapy for multiple sclerosis, neuromyelitis optica spectrum disorders and MOG-antibody-associated diseases
J. Rigal et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)
Late-onset neutropenia in a multiple sclerosis patient after first dose ocrelizumab switched from rituximab
Michael Auer et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)
Five years of ocrelizumab in relapsing multiple sclerosis OPERA studies open-label extension
Stephen L. Hauser et al.
NEUROLOGY (2020)
Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis The VELOCE study
Amit Bar-Or et al.
NEUROLOGY (2020)
Ofatumumab versus Teriflunomide in Multiple Sclerosis
Stephen L. Hauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
A pathogenic and clonally expanded B cell transcriptome in active multiple sclerosis
Akshaya Ramesh et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
B cells reappear less mature and more activated after their anti-CD20-mediated depletion in multiple sclerosis
Nitzan Nissimov et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Transcriptomic and clonal characterization of T cells in the human central nervous system
Jenna L. Pappalardo et al.
SCIENCE IMMUNOLOGY (2020)
Disease activity in pregnancy and postpartum in women with MS who suspended rituximab and natalizumab
Neda Razaz et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2020)
Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial
Jerry S. Wolinsky et al.
LANCET NEUROLOGY (2020)
Risk of Malignancies in Patients with Rheumatoid Arthritis Treated with Rituximab: Analyses of Global Postmarketing Safety Data and Long-Term Clinical Trial Data
Paul Emery et al.
RHEUMATOLOGY AND THERAPY (2020)
B cell depletion with ublituximab reshapes the T cell profile in multiple sclerosis patients
Amy E. Lovett-Racke et al.
JOURNAL OF NEUROIMMUNOLOGY (2019)
Impact of B cells to the pathophysiology of multiple sclerosis
Borros M. Arneth
JOURNAL OF NEUROINFLAMMATION (2019)
Imaging Mass Cytometry and Single-Cell Genomics Reveal Differential Depletion and Repletion of B-Cell Populations Following Ofatumumab Treatment in Cynomolgus Monkeys
Diethilde Theil et al.
FRONTIERS IN IMMUNOLOGY (2019)
Early adaptive immune activation detected in monozygotic twins with prodromal multiple sclerosis
Eduardo Beltran et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Anti-CD20 therapy depletes activated myelin-specific CD8+ T cells in multiple sclerosis
Joseph J. Sabatino et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Proinflammatory CD20+ T cells in the pathogenesis of multiple sclerosis
Marina R. von Essen et al.
BRAIN (2019)
Recirculating Intestinal IgA-Producing Cells Regulate Neuroinflammation via IL-10
Olga L. Rojas et al.
CELL (2019)
Late-onset neutropenia following ocrelizumab therapy for multiple sclerosis
Bruce A. Cohen
NEUROLOGY (2019)
Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis
Yvonne Naegelin et al.
JAMA NEUROLOGY (2019)
Ocrelizumab Depletes CD20+ T Cells in Multiple Sclerosis Patients
Stefan Gingele et al.
CELLS (2019)
Pregnancy outcomes in patients treated with ocrelizumab
C. Oreja-Guevara et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2019)
T helper 17.1 cells associate with multiple sclerosis disease activity: perspectives for early intervention
Jamie van Langelaar et al.
BRAIN (2018)
The compartmentalized inflammatory response in the multiple sclerosis brain is composed of tissue-resident CD8+T lymphocytes and B cells
Joana Machado-Santos et al.
BRAIN (2018)
Ublituximab for the treatment of CD20 positive B-cell malignancies
Hani M. Babiker et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2018)
Late-onset neutropenia and neurological relapse, during long-term rituximab therapy in myelin oligodendrocyte glycoprotein-antibody spectrum disorder
Damien Biotti et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
Xavier Montalban et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis The MIRROR study
Amit Bar-Or et al.
NEUROLOGY (2018)
Multiple Sclerosis: Mechanisms and Immunotherapy
Clare Baecher-Allan et al.
NEURON (2018)
Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis
Mathias Granqvist et al.
JAMA NEUROLOGY (2018)
Late-onset neutropenia and neurological relapse, during long-term rituximab therapy in myelin oligodendrocyte glycoprotein-antibody spectrum disorder
Damien Biotti et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
Xavier Montalban et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Memory B Cells Activate Brain-Homing, Autoreactive CD4+ T Cells in Multiple Sclerosis
Ivan Jelcic et al.
CELL (2018)
Functional characterization of reappearing B cells after anti-CD20 treatment of CNS autoimmune disease
Darius Haeusler et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Rituximab before and during pregnancy A systematic review, and a case series in MS and NMOSD
Gitanjali Das et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2018)
Emerging Role of the Spleen in the Pharmacokinetics of Monoclonal Antibodies, Nanoparticles and Exosomes
Mauro Cataldi et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis
Jeffrey M. Gelfand et al.
NEUROTHERAPEUTICS (2017)
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
S. L. Hauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
X. Montalban et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Overexpression of the Cytokine BAFF and Autoimmunity Risk
M. Steri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Phenotypic and functional characterization of T cells in white matter lesions of multiple sclerosis patients
Gijsbert P. van Nierop et al.
ACTA NEUROPATHOLOGICA (2017)
Robust memory responses against influenza vaccination in pemphigus patients previously treated with rituximab
Alice Cho et al.
JCI INSIGHT (2017)
Adaptive human immunity drives remyelination in a mouse model of demyelination
Mohamed El Behi et al.
BRAIN (2017)
The topograpy of demyelination and neurodegeneration in the multiple sclerosis brain
Lukas Haider et al.
BRAIN (2016)
Rituximab associated late-onset neutropenia-a rheumatology case series and review of the literature
William E. Monaco et al.
CLINICAL RHEUMATOLOGY (2016)
Features of Human CD3+CD20+ T Cells
Elisabeth Schuh et al.
JOURNAL OF IMMUNOLOGY (2016)
Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque
Josa M. Frischer et al.
ANNALS OF NEUROLOGY (2015)
Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years
Ronald F. van Vollenhoven et al.
JOURNAL OF RHEUMATOLOGY (2015)
Functional inflammatory profiles distinguish myelin-reactive T cells from patients with multiple sclerosis
Yonghao Cao et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: data from the AutoImmunity and Rituximab registry
J. H. Salmon et al.
RMD OPEN (2015)
Late-onset neutropenia following rituximab treatment for rheumatologic conditions
Gabriel S. Breuer et al.
CLINICAL RHEUMATOLOGY (2014)
Intrathecal Rituximab Therapy in Multiple Sclerosis: Review of Evidence Supporting the Need for Future Trials
Mickael Bonnan et al.
CURRENT DRUG TARGETS (2014)
Rituximab Efficiently Depletes Increased CD20-Expressing T Cells in Multiple Sclerosis Patients
Arumugam Palanichamy et al.
JOURNAL OF IMMUNOLOGY (2014)
Late-onset Neutropenia in Patients with Rheumatoid Arthritis after Treatment with Rituximab
Rita Abdulkader et al.
JOURNAL OF RHEUMATOLOGY (2014)
Antibody-dependent cellular cytotoxicity of the optimized anti-CD20 monoclonal antibody ublituximab on chronic lymphocytic leukemia cells with the 17p deletion
M. Le Garff-Tavernier et al.
LEUKEMIA (2014)
Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis A phase 2 study
Per S. Sorensen et al.
NEUROLOGY (2014)
Defining the clinical course of multiple sclerosis The 2013 revisions
Fred D. Lublin et al.
NEUROLOGY (2014)
Effect of Methotrexate, Anti-Tumor Necrosis Factor α, and Rituximab on the Immune Response to Influenza and Pneumococcal Vaccines in Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Charlotte Hua et al.
ARTHRITIS CARE & RESEARCH (2014)
Late-onset neutropenia during long-term rituximab therapy in neuromyelitis optica
Annika Plate et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2014)
Reduced antibody formation after influenza vaccination in patients with neuromyelitis optica spectrum disorder treated with rituximab
W. Kim et al.
EUROPEAN JOURNAL OF NEUROLOGY (2013)
Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties
Christian Klein et al.
MABS (2013)
Epstein-Barr virus in oral shedding of children with multiple sclerosis
Carmen Yea et al.
NEUROLOGY (2013)
Increased CD8+T Cell Response to Epstein-Barr Virus Lytic Antigens in the Active Phase of Multiple Sclerosis
Daniela F. Angelini et al.
PLOS PATHOGENS (2013)
Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis
Sung R. Choi et al.
BRAIN (2012)
IgG Placental Transfer in Healthy and Pathological Pregnancies
Patricia Palmeira et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2012)
B cell exchange across the blood-brain barrier in multiple sclerosis
H. -Christian von Buedingen et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Pregnancy outcomes after maternal exposure to rituximab
Eliza F. Chakravarty et al.
BLOOD (2011)
Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis
Owain W. Howell et al.
BRAIN (2011)
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
Ludwig Kappos et al.
LANCET (2011)
Abnormal B-Cell Cytokine Responses A Trigger of T-Cell Mediated Disease in MS?
Amit Bar-Or et al.
ANNALS OF NEUROLOGY (2010)
Elevated Epstein-Barr Virus-Encoded Nuclear Antigen-1 Immune Responses Predict Conversion to Multiple Sclerosis
Jan D. Luenemann et al.
ANNALS OF NEUROLOGY (2010)
A Gradient of Neuronal Loss and Meningeal Inflammation in Multiple Sclerosis
Roberta Magliozzi et al.
ANNALS OF NEUROLOGY (2010)
Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma
F. Morschhauser et al.
ANNALS OF ONCOLOGY (2010)
Immunization Responses in Rheumatoid Arthritis Patients Treated With Rituximab Results From a Controlled Clinical Trial
Clifton O. Bingham et al.
ARTHRITIS AND RHEUMATISM (2010)
Humoral Responses After Influenza Vaccination Are Severely Reduced in Patients With Rheumatoid Arthritis Treated With Rituximab
Sander van Assen et al.
ARTHRITIS AND RHEUMATISM (2010)
CD20 deficiency in humans results in impaired T cell-independent antibody responses
Taco W. Kuijpers et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Evolution of anti-CD20 monoclonal antibody therapeutics in oncology
Ezogelin Oflazoglu et al.
MABS (2010)
The immunogenicity of humanized and fully human antibodies Residual immunogenicity resides in the CDR regions
Fiona A. Harding et al.
MABS (2010)
Late-Onset Neutropenia After Rituximab Treatment Case Series and Comprehensive Review of the Literature
Ofir Wolach et al.
MEDICINE (2010)
CURRENT CONCEPTS The Enigma of Spontaneous Preterm Birth
Louis J. Muglia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Rituximab in Patients with Primary Progressive Multiple Sclerosis Results of a Randomized Double-Blind Placebo-Controlled Multicenter Trial
Kathleen Hawker et al.
ANNALS OF NEUROLOGY (2009)
The relation between inflammation and neurodegeneration in multiple sclerosis brains
Josa M. Frischer et al.
BRAIN (2009)
Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20
Jiamu Du et al.
MOLECULAR IMMUNOLOGY (2009)
Ofatumumab, a Human Mab Targeting a Membrane-Proximal Small-Loop Epitope On CD20, Induces Potent NK Cell-Mediated ADCC.
Jenny L. Craigen et al.
BLOOD (2009)
Induction of cytosolic calcium flux by CD20 is dependent upon B cell antigen receptor signaling
Claire A. Walshe et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Invited article: Inhibition of B cell functions - Implications for neurology
Marinos C. Dalakas
NEUROLOGY (2008)
B-cell depletion with Rituximab in relapsing-remitting multiple sclerosis
Stephen L. Hauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production
Frederic Lavie et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Rheumatoid arthritis and reproduction
Amit Golding et al.
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA (2007)
Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology
Roberta Magliozzi et al.
BRAIN (2007)
Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients
Anne H. Cross et al.
JOURNAL OF NEUROIMMUNOLOGY (2006)
The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20
Jessica L. Teeling et al.
JOURNAL OF IMMUNOLOGY (2006)
Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis
O Stüve et al.
ARCHIVES OF NEUROLOGY (2005)
Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse
S Vukusic et al.
BRAIN (2004)
Share Paper
